Unresectable Gastroesophageal Junction Adenocarcinoma Not Yet Recruiting Phase 2 / 3 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Not Yet Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06203600Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE TrialTreatment